Chronic proliferative synovitis sits in a frustrating diagnostic middle ground. The joint lining thickens, fills with immune cells, grows new blood vessels it should not have, and progressively damages cartilage and bone — yet the condition is routinely described to patients in the vaguest possible terms: "joint inflammation," "early arthritis," or simply "synovitis." That kind of framing does not give you much to work with.

Joint bleeding while on anticoagulant therapy places you in a narrow corridor: the medication is protecting you from a potentially life-threatening clot, yet the same drug raises your risk of bleeding into the dense, pressure-sensitive tissue of a joint.

When joint pain arrives without a clean explanation — no prior injury, no obvious autoimmune diagnosis, no real response to standard anti-inflammatories — mycoplasma infection sits in a diagnostic blind spot that most practitioners rarely examine.